Home Compare LLY vs MRK
Stock Comparison · Industry comparison · Drug Manufacturers - General

Eli Lilly and Company vs Merck & Co.: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Eli Lilly and Company carrying a narrow edge on growth. Merck still leads on valuation and stability, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in growth, but profitability adds another real layer to the result.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. LLY and MRK share the same industry classification.

For a similarity-based comparison, see how Eli Lilly and Company and Merck each position within their functional peer groups in AssetNext.

Peer-Relative Score
LLY
Eli Lilly and Company
68
Peer-Score
Signal qualityHigh
vs
MRK
Merck & Co., Inc.
63
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: LLY vs MRK Profitability 100 62 Stability 34 57 Valuation 44 88 Growth 88 31 LLY MRK
Gap Ranking
#1 Growth +57
#2 Valuation +44
#3 Profitability +38
#4 Stability +23
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for LLY and MRK Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer LLYMRK Relative valuation Structural strength

Eli Lilly and Company looks stronger, but the price setup still looks more supportive for Merck & Co., Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Eli Lilly and Company ranks near the top of the group on growth; Merck & Co., Inc. sits in the weaker half.
Valuation
On valuation, the edge is clear — both rank well, but Merck & Co., Inc. sits noticeably higher.
Growth — Dominant Gap
LLY
88
MRK
31
Gap+57in favour of LLY

Growth adds another layer to the lead, with a very wide gap in revenue growth between the two companies.

What keeps the gap from being one-sided

There is still a strong counterforce in valuation, so the lead stays clear without becoming a sweep.

What this means for the comparison

The page question resolves through growth, but valuation and current pricing still keep the broader comparison from reading as fully aligned.

Explore full peer positioning in AssetNext

Break down the LLY vs MRK comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how LLY and MRK each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.